NASDAQ:DMTK DermTech (DMTK) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free DMTK Stock Alerts $0.59 -0.03 (-4.87%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.58▼$0.6350-Day Range$0.59▼$1.3652-Week Range$0.58▼$3.93Volume178,890 shsAverage Volume314,957 shsMarket Capitalization$20.27 millionP/E RatioN/ADividend YieldN/APrice Target$2.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get DermTech alerts: Email Address DermTech MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside306.0% Upside$2.38 Price TargetShort InterestBearish10.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.06Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.26) to ($2.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.91 out of 5 starsMedical Sector812th out of 907 stocksMedical Laboratories Industry17th out of 19 stocks 3.0 Analyst's Opinion Consensus RatingDermTech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageDermTech has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.05% of the float of DermTech has been sold short.Short Interest Ratio / Days to CoverDermTech has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in DermTech has recently decreased by 2.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDermTech does not currently pay a dividend.Dividend GrowthDermTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DMTK. Previous Next 1.6 News and Social Media Coverage News SentimentDermTech has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for DermTech this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added DermTech to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DermTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of DermTech is held by insiders.Percentage Held by InstitutionsOnly 20.45% of the stock of DermTech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for DermTech are expected to grow in the coming year, from ($2.26) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DermTech is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DermTech is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDermTech has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About DermTech Stock (NASDAQ:DMTK)DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.Read More DMTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DMTK Stock News HeadlinesApril 21, 2024 | americanbankingnews.comDermTech (NASDAQ:DMTK) Rating Reiterated by StephensApril 21, 2024 | americanbankingnews.comLake Street Capital Reiterates "Hold" Rating for DermTech (NASDAQ:DMTK)April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 21, 2024 | americanbankingnews.comDermTech (NASDAQ:DMTK) Stock Rating Reaffirmed by BTIG ResearchApril 20, 2024 | investing.comDermTech stock downgraded by BTIG amid strategic reviewApril 19, 2024 | msn.comBTIG Downgrades DermTech (DMTK)April 19, 2024 | markets.businessinsider.comWhat Analysts Are Saying About DermTech StockApril 18, 2024 | marketwatch.comDermTech to Slash 56% of Workforce, Explore OptionsApril 26, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 18, 2024 | msn.comDermTech exploring strategic alternatives, cutting 56% of staffApril 18, 2024 | businesswire.comDermTech to Explore Strategic Alternatives and Implement Restructuring PlanApril 17, 2024 | finance.yahoo.comDermTech, Inc. (DMTK)April 17, 2024 | americanbankingnews.comDermTech (NASDAQ:DMTK) Trading Down 0.9%March 8, 2024 | businesswire.comDermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative DermatologyMarch 7, 2024 | investing.comStephens cuts DermTech stock target to $1.50, keeps Equal Weight ratingMarch 2, 2024 | finance.yahoo.comDermTech, Inc. (NASDAQ:DMTK) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | benzinga.comRecap: DermTech Q4 EarningsFebruary 29, 2024 | businesswire.comDermTech Reports Fourth-Quarter 2023 Financial ResultsFebruary 28, 2024 | msn.comDermTech Q4 2023 Earnings PreviewFebruary 13, 2024 | finance.yahoo.comDermTech Announces Release Date for Fourth-quarter 2023 Financial ResultsFebruary 1, 2024 | markets.businessinsider.comDermTech International Registered ShsJanuary 31, 2024 | marketwatch.comDermTech to Cut Workforce by 15%, Six Months After Round of LayoffsJanuary 31, 2024 | finance.yahoo.comDermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline OperationsJanuary 18, 2024 | msn.comDermTech study finds melanoma test effective for all skin typesJanuary 18, 2024 | finance.yahoo.comDermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin TypesJanuary 16, 2024 | finance.yahoo.comDermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on AssayJanuary 8, 2024 | marketwatch.comDermTech Shares Rise 14% After Positive Results in Melanoma Test StudySee More Headlines Receive DMTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today4/25/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:DMTK CUSIPN/A CIK1651944 Webwww.dermtech.com Phone(858) 450-4222FaxN/AEmployees206Year FoundedN/APrice Target and Rating Average Stock Price Target$2.38 High Stock Price Target$5.00 Low Stock Price Target$0.63 Potential Upside/Downside+306.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,890,000.00 Net Margins-659.57% Pretax Margin-659.57% Return on Equity-123.96% Return on Assets-67.94% Debt Debt-to-Equity RatioN/A Current Ratio4.59 Quick Ratio4.52 Sales & Book Value Annual Sales$15.30 million Price / Sales1.32 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book0.35Miscellaneous Outstanding Shares34,620,000Free Float32,857,000Market Cap$20.27 million OptionableOptionable Beta2.52 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Kevin Sun M.B.A. (Age 46)CFO, Treasurer & Secretary Comp: $461.92kMr. Ray Akhavan Esq. (Age 55)J.D., General Counsel Comp: $413.06kMr. Bret Christensen (Age 53)President, CEO & Director Mr. William W. ZondlerChief Information OfficerMr. Steve E. KunszaboSenior Director of Investor RelationsMs. Jennifer EilembergChief Compliance OfficerDr. Burkhard Jansen M.D. (Age 58)Chief Medical Affairs Officer Comp: $419.8kDr. Loren Clarke M.D.Chief Medical OfficerDr. Steven Stone Ph.D.Senior Vice President of Research & DevelopmentMr. Mark AguillardChief Commercial OfficerMore ExecutivesKey CompetitorsExagenNASDAQ:XGNPsychemedicsNASDAQ:PMDCentogeneNASDAQ:CNTGBioNexus Gene LabNASDAQ:BGLCAkuminNASDAQ:AKUMQView All CompetitorsInsiders & InstitutionsKing Luther Capital Management CorpSold 15,000 shares on 2/9/2024Ownership: 0.553%Texas Capital Bank Wealth Management Services IncBought 60,000 shares on 2/8/2024Ownership: 0.350%Savant Capital LLCBought 35,184 shares on 2/5/2024Ownership: 0.103%Simplex Trading LLCBought 100 shares on 2/2/2024Ownership: 0.000%Quantum Private Wealth LLCBought 8,634 shares on 1/30/2024Ownership: 0.097%View All Insider TransactionsView All Institutional Transactions DMTK Stock Analysis - Frequently Asked Questions Should I buy or sell DermTech stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DMTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DMTK, but not buy additional shares or sell existing shares. View DMTK analyst ratings or view top-rated stocks. What is DermTech's stock price target for 2024? 3 Wall Street analysts have issued 12 month price objectives for DermTech's stock. Their DMTK share price targets range from $0.63 to $5.00. On average, they anticipate the company's share price to reach $2.38 in the next twelve months. This suggests a possible upside of 306.0% from the stock's current price. View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts. How have DMTK shares performed in 2024? DermTech's stock was trading at $1.75 at the start of the year. Since then, DMTK shares have decreased by 66.5% and is now trading at $0.5854. View the best growth stocks for 2024 here. When is DermTech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our DMTK earnings forecast. How were DermTech's earnings last quarter? DermTech, Inc. (NASDAQ:DMTK) posted its earnings results on Thursday, February, 29th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.02. The business had revenue of $3.92 million for the quarter, compared to analysts' expectations of $4.05 million. DermTech had a negative net margin of 659.57% and a negative trailing twelve-month return on equity of 123.96%. What other stocks do shareholders of DermTech own? Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH). How do I buy shares of DermTech? Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DMTK) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DermTech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
